SUBJECT: System Changes to Implement Epoetin Alfa Biosimilar, Retacrit for End Stage Renal Disease (ESRD) and Acute Kidney Injury (AKI) Claims

I. SUMMARY OF CHANGES: The purpose of this Change Request (CR) is to make system changes for End Stage Renal Disease (ESRD) and Acute Kidney Injury (AKI) claims.

The CR will also make revisions to the following manuals:

Publication 100-02, Chapter 11, Section 100.6 - Applicability of Specific ESRD PPS Policies to AKI Dialysis, of the Medicare Benefits Policy manual.

Publication 100-04, Chapter 8, Section 60.4.2 - Facility Billing Requirements for ESAs, of the Medicare Claims Processing manual.

EFFECTIVE DATE: January 1, 2019
*Unless otherwise specified, the effective date is the date of service.
IMPLEMENTATION DATE: January 7, 2019

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)
R=REVISED, N=NEW, D=DELETED-Only One Per Row.

<table>
<thead>
<tr>
<th>R/N/D</th>
<th>CHAPTER / SECTION / SUBSECTION / TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
<td>11/100/100.6/Applicability of Specific ESRD PPS Policies to AKI Dialysis</td>
</tr>
</tbody>
</table>

III. FUNDING:
For Medicare Administrative Contractors (MACs):
The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:
Business Requirements
Manual Instruction
SUBJECT: System Changes to Implement Epoetin Alfa Biosimilar, Retacrit for End Stage Renal Disease (ESRD) and Acute Kidney Injury (AKI) Claims

EFFECTIVE DATE: January 1, 2019
*Unless otherwise specified, the effective date is the date of service.
IMPLEMENTATION DATE: January 7, 2019

I. GENERAL INFORMATION

A. Background: On June 29, 2015, the Trade Preferences Extension Act of 2015 was enacted in which section 808 amended Section 1861(s)(2)(F) of the Social Security Act (42 U.S.C. 1395x(s)(2)(F)) by extending renal dialysis services paid under section 1881(b)(14) to beneficiaries with acute kidney injury (AKI), effective January 1, 2017. Change Requests (CRs) 9598 and 9814 implemented the initial requirements for this legislation.

B. Policy: Billing for consolidated renal dialysis services for beneficiaries with Acute Kidney Injury

This Change Request (CR) updates the list of supplies, drugs, and labs included in the ESRD consolidated billing list and therefore included in the base rate payment for AKI. This includes erythropoietin stimulating agents billed with the ESRD-specific HCPCS or the non-ESRD specific HCPCS.

With this CR, we are adding Q5106 - Injection, epoetin alfa, biosimilar, (Retacrit) (for non-ESRD use), 1000 units to the list established in CR 9987:

Claims that include Q5106 with dates of service between July 1, 2018 and December 31, 2018 will need to be reprocessed.

II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

<table>
<thead>
<tr>
<th>Number</th>
<th>Requirement</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>10839 - 02.1</td>
<td>Medicare contractors shall not separately pay HCPCS code Q5106 (not found on the consolidated billing list) for AKI claims for dates of service on or after July 1, 2018.</td>
<td>A/B MAC</td>
</tr>
<tr>
<td></td>
<td>AKI claims = Type of Bill 72X, submitted with</td>
<td>D M E F I S M C V C W F</td>
</tr>
</tbody>
</table>

X
<table>
<thead>
<tr>
<th>Requirement</th>
<th>Responsibility</th>
<th>A/B MAC</th>
<th>DME</th>
<th>Shared-System Maintainers</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>condition code 84, CPT code G0491 and one of the following ICD-10 diagnosis codes:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. N17.0 Acute kidney failure with tubular necrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. N17.1 Acute kidney failure with acute cortical necrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. N17.2 Acute kidney failure with medullary necrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. N17.8 Other acute kidney failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. N17.9 Acute kidney failure, unspecified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. T79.5XXA Traumatic anuria, initial encounter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. T79.5XXD Traumatic anuria, subsequent encounter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. T79.5XXS Traumatic anuria, sequela</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. N99.0 Post-procedural (acute)(chronic) renal failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOTE: Line should be indicated as covered. Lines billed with modifier AY should not receive separate payment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicare contractors shall use the following ANSI information:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Code: CO - Contractual Obligation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARC 97 The benefit for this service is included in the payment/allowance for another service/procedure that has already been adjudicated. Note: Refer to the 835 Healthcare Policy Identification Segment (loop</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2110 Service Payment Information REF), if present.

10839 - 02.2 Medicare contractors shall mass adjust AKI claims where HCPCS code Q5106 is present for dates of service on or after July 1, 2018 through December 31, 2018. Mass adjustment should be completed within 90 days of the implementation date of this transmittal.

10839 - 02.3 Medicare contractors shall update reason code 31643 to include HCPCS codes Q5105 when submitted with revenue codes 634/635 on type of bill 12X, 13X, 72X and 85X, effective for dates of service on or after July 1, 2018.

10839 - 02.4 Medicare contractors shall establish recurring hours to update the list of services not separately payable on Acute Kidney Injury claims.

10839 - 02.5 Medicare contractors shall be aware of revisions to Pub. 100-02, Chapter 11, Section 100.6 - Applicability of Specific ESRD PPS Policies to AKI Dialysis, of the Medicare Benefits Policy manual.

III. PROVIDER EDUCATION TABLE

10839 - 02.6 MLN Article: CMS will make available an MLN Matters provider education article that will be marketed through the MLN Connects weekly newsletter shortly after the CR is released. MACs shall follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1, instructions for distributing MLN Connects information to providers, posting the article or a direct link to the article on your website, and including the article or a direct link to the article in your bulletin or newsletter. You may supplement MLN Matters articles with localized information benefiting your provider community in billing and administering the Medicare program correctly. Subscribe to the “MLN Matters” listserv to get article release notifications, or review them in the MLN Connects weekly newsletter.
IV. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements: N/A

"Should" denotes a recommendation.

<table>
<thead>
<tr>
<th>X-Ref Requirement Number</th>
<th>Recommendations or other supporting information:</th>
</tr>
</thead>
</table>

Section B: All other recommendations and supporting information: N/A

V. CONTACTS

Pre-Implementation Contact(s): Cindy Pitts, Cindy.Pitts@cms.hhs.gov, Shauntari Cheely, Shauntari.Cheely@cms.hhs.gov, Tracey Mackey, Tracey.Mackey@cms.hhs.gov

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VI. FUNDING

Section A: For Medicare Administrative Contractors (MACs):
The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0
A. Dialysis Modality

Beneficiaries with AKI can receive their dialysis via the most clinically appropriate in-facility modality.

B. Uncompleted Dialysis Treatment

Generally, CMS only pays for one treatment per day across all settings. However, similar to the policy applied under the ESRD PPS for treatments for patients with ESRD, in the interest of fairness and in accordance with Chapter 8, section 10.2 of the Medicare Claims Processing Manual, if a dialysis treatment is started, that is, a patient is connected to the machine and a dialyzer and blood lines are used, but the treatment is not completed for some unforeseen, but valid reason, for example, a medical emergency when the patient must be rushed to an emergency room, both the ESRD facility and the hospital would be paid. This is considered to be a rare occurrence that must be fully documented to the A/B MAC's satisfaction.

C. Home and Self-Dialysis

Due to the nature of AKI, dialysis treatments at home or self-dialysis in the dialysis facility are not permitted. Specifically, these patients require supervision by qualified staff during their dialysis and close monitoring through laboratory tests to ensure that they are receiving the necessary care to improve their condition and get off of dialysis. Therefore, the home dialysis benefit does not extend to beneficiaries with AKI.

D. Vaccines and Their Administration

Section 1881(b)(14)(B) of the Act specifically excludes vaccines covered under section 1861(s)(10) of the Act from the ESRD PPS. However, ESRD facilities are identified as an entity that can bill Medicare for vaccines and their administration. Therefore, ESRD facilities may furnish vaccines to beneficiaries with AKI and bill Medicare in accordance with billing requirements in the Medicare Claims Processing Manual (Pub. 100-04, Chapter 18 Preventive and Screening Services, section 10.2). The staff time associated with vaccine administration is covered in the AKI dialysis payment rate.

E. Telehealth

Since telehealth dialysis services are limited to renal dialysis services for home dialysis patients telehealth related to renal dialysis services is not available for beneficiaries with AKI.

F. ESRD Conditions for Coverage (CfCs)

The ESRD CfCs at 42 CFR part 494 are health and safety standards that all Medicare participating dialysis facilities must meet. These standards set baseline requirements for patient safety, infection control, care planning, staff qualifications, record keeping, and other matters to ensure that all patients, including ESRD and AKI patients, receive safe and appropriate care.

G. Payment for Erythropoietin Stimulating Agents (ESAs) and the ESA Monitoring Policy for AKI Patients
ESAs are included in the bundled payment amount for treatments administered to patients with AKI. The Non-ESRD HCPCS codes should be used (J0881, J0883, J0885, J0888, Q0138, Q5106) and reported using revenue code 0636.

The ESA monitoring policy has not yet been extended to AKI patients receiving treatment in an ESRD facility. Since this policy is not applicable to these treatments, the value codes used to report hemoglobin and hematocrit levels are not required when billing for ESAs.